Latest filing published 24 Mar 2026 for Neuronetics, Inc., €19k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Steven Pfanstiel across 2 companies, led by Marinus Pharmaceuticals, Inc. and Neuronetics, Inc. In total, 17 filings cover trades dated from 4 February 2022 to 19 March 2026.
Sales make up the whole of the open-market record (5 sales, €77k). Other entries cover 10 share grants. Since January 2026: no purchases and 1 sale on the market.
The record was last updated on 24 March 2026 with an open-market sale (€19k) in Neuronetics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations